Pharmacology August 2025: Ukraine at the epicenter of change

August 2025 will be remembered for several fateful decisions in international pharma, but it also brought challenges for Ukraine — from advertising-related fines to new mobilization standards. All of these events shape the context in which our healthcare system operates.

⚖️ Antitrust decisions and the fight against unfair advertising

The Antimonopoly Committee of Ukraine has made an important decision: two pharmaceutical companies — Gledfarm LTD and Ilan Farm LLC — were fined for misleading advertising of medicines.

This news is both disturbing and necessary:

• It is disturbing because it demonstrates that even in the pharma market, where trust is vital, companies are sometimes willing to view ethical boundaries as fluid.
• It is necessary because it shows that the regulator is ready to act. This is a signal to all market participants: advertising is not a zone of freedom without limits, but a zone of responsibility.

🚨 New mobilization requirement for women with medical and pharmaceutical education

On August 30, 2025, Cabinet Resolution No. 916 came into force, automatically registering women with medical or pharmaceutical education for military registration.

This decision has strong symbolism:

• Pharmaceutical and medical workers find themselves between two poles: specialists who support the health of the nation, and potential mobilized resources of the state.
• This is a signal for institutions: educational programs, personnel reserves, and career strategies must take this “status uncertainty” into account.

This move is a reminder: pharma is not an isolated sector. It is intertwined with national security.

🧪 Recognized new drugs: global background, local consequences

In August, the FDA approved several new drugs that could change the global pharmaceutical landscape. Among them:

• Papzimeos (zopapogene imadenovec-drba) is the first non-replicative adenoviral immunotherapy for the treatment of recurrent respiratory papillomavirus.
• Tonmya (TNX-102 SL, sublingual cyclobenzaprine) — for the treatment of fibromyalgia — is the first new drug in many years in this niche.

For Ukraine, such approvals are not just “a new name on the list.” They are:

• Future import application guidelines
• Benchmarks for assessing the local regulatory process
• Potential drugs that will appear on the market in a few years — and change therapeutic lines

This trend creates expectations and responsibility: we must analyze now, prepare standards, and think about access.

🤖 AI and approval prediction: new intelligence at the service of pharma

In August, a publication was published about DrugReasoner — an LLM model that predicts the probability of approval of new small molecules, with a step-by-step explanation of the solution.

What does this mean for Ukraine:

• Research centers can implement AI prediction frameworks already at the preclinical stage
• Regulators can use similar tools as a supporting layer for risk analysis
• For startups, the ability to screen out “toxic” candidates faster

This is a huge potential, but also a temptation: a misanthropic code of trust — the model does not replace evidence, but it can strengthen decision-making.

🏭 “From Legacy to Leadership”: a strategic institutional initiative

A new long-term project together with the Volkswagen Stiftung — “From Legacy to Leadership” — aims to rethink Ukraine’s pharmaceutical potential, building on its industrial heritage (e.g., Soviet pharmaceutical plants) and integrating the industry into the modern European market.

Key tasks:

• rearmament of enterprises
• partnership with international research centers
• adaptation of European standards GMP / GLP
• development of exports of innovative products

This project sets a strategic benchmark: not just survival, but becoming a leader.

🦠 System Resilience: HIV, TB and Pharma in Ukraine

According to the Global Fund, over the past 20 years, Ukraine has significantly reduced tuberculosis rates and maintained access to therapies for people with HIV.

But in light of shortages, logistical issues, and geopolitics, these gains are becoming vulnerable.

This is a reminder: pharmacy must be a redundant system that works not only in peacetime, but also under pressure.

🔍 Summary

1. Advertising control is the key to maintaining trust.
2. Mobilization of the pharmaceutical sector is a reminder that women in pharmacy are not only personnel, but also part of systemic security.
3. New drugs are like beacons of change, but at the same time they are tests for regulation and accessibility.
4. AI forecasting models are a tool of the future that is worth testing today.
5. Strategic projects (Legacy→Leadership) are the foundation for a new pharmacy.
6. Pharmacy in the fight against infections is a background that cannot be ignored.